Events

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

The presenter will discuss the routine care the mare requires throughout the year. Topics will include preparing the mare through anestrus to managing her cycle to conception. The medications and tools used in the breeding shed will be discussed along with maintenance considerations for the pregnant mare from conception to foaling.

07:00 PM EST

RACE# 27059-898393

1 RACE-Approved Credit Hour
 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM CST

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

Canine Hyperadrenocorticism (Cushing’s Disease) can be a challenging yet rewarding disease to manage. This presentation will review all aspects of Cushing’s: basic pathophysiology, clinical signs, diagnostics, differentiating tests, treatment and monitoring. A series of cases to increase  understanding of managing Cushing’s patients will be presented and the final  section highlights ways to  enhance owner compliance. 

07:00 PM EST

1.5 RACE-Approved Credits  

RACE# 27059-869593 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM MST

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM MST

1 RACE-Approved Credit  

RACE# 27059-918761

Canine Hyperadrenocorticism (Cushing’s Disease) can be a challenging yet rewarding disease to manage. This presentation will review all aspects of Cushing’s: basic pathophysiology, clinical signs, diagnostics, differentiating tests, treatment and monitoring. A series of cases to increase  understanding of managing Cushing’s patients will be presented and the final  section highlights ways to  enhance owner compliance. 

10:00 PM EST

1.5 RACE-Approved Credits  

RACE# 27059-869593 

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM PST

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

10:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM PST

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

Zennovation in Sedation: Rethinking What is Possible

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

Verdinexor: A Novel Oral Therapy for Canine Lymphoma 

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM PST

2 RACE-Approved Credit 

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

02:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

02:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

Canine Hyperadrenocorticism (Cushing’s Disease) can be a challenging yet rewarding disease to manage. This presentation will review all aspects of Cushing’s: basic pathophysiology, clinical signs, diagnostics, differentiating tests, treatment and monitoring. A series of cases to increase understanding of managing Cushing’s patients will be presented and the final section highlights ways to enhance owner compliance.

12:00 PM EST

1.5 RACE-Approved Credit  

RACE# 27059-869593

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM Central

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

Part 2: This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events.

1:00 PM Central

2 RACE-Approved Credit  

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM Central

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

06:30 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

06:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

07:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-900255 

Canine otitis externa is one of the most frequently encountered conditions in small animal veterinary practice. This presentation explores the causes of canine otitis externa including the predisposing, primary and perpetuating factors, the importance of otic cytology, and the essential treatment modalities to help ensure clinical resolution. The development of a long-term maintenance cleaning and allergy management plan will also be discussed.

10:00 PM EST

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

With dermatologic conditions making up a large volume of the caseload in companion animal medicine and with antimicrobial resistance on the rise, topical therapies need to play a bigger role in dermatologic therapy. This presentation will discuss why topical therapies are helpful and how cytology helps guide topical product choice. The most common active ingredients in topical products for companion animals will be highlighted including their mechanism of action and suggested use. By having a complete understanding of active ingredients, veterinarians will be better equipped to make a topical product selection. Compliance strategies will be discussed to help ensure that what a veterinarian prescribes actually gets used.

12:00 PM EST

RACE# 27059-906349

1 RACE-Approved Credit Hour

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

Canine otitis externa is one of the most frequently encountered conditions in small animal veterinary practice. This presentation explores the causes of canine otitis externa including the predisposing, primary and perpetuating factors, the importance of otic cytology, and the essential treatment modalities to help ensure clinical resolution. The development of a long-term maintenance cleaning and allergy management plan will also be discussed.

12:00 PM EST

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

07:00 PM PDT

1 RACE-Approved Credit  

RACE# 27059-900255 

With dermatologic conditions making up a large volume of the caseload in companion animal medicine and with antimicrobial resistance on the rise, topical therapies need to play a bigger role in dermatologic therapy. This presentation will discuss why topical therapies are helpful and how cytology helps guide topical product choice. The most common active ingredients in topical products for companion animals will be highlighted including their mechanism of action and suggested use. By having a complete understanding of active ingredients, veterinarians will be better equipped to make a topical product selection. Compliance strategies will be discussed to help ensure that what a veterinarian prescribes actually gets used.

10:00 PM EST

RACE# 27059-906349

1 RACE-Approved Credit Hour

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

07:00 PM PDT

1 RACE-Approved Credit  

RACE# 27059-900255 

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

02:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-900255 

The presenter reviews equine regenerative therapy. Focus areas include basic principles of regenerative medicine, FDA regulations, and types of autologous blood products. The types of medical devices necessary for processing autologous blood products including centrifugation, filtration, and incubation are all discussed. Additionally, a meta-analysis of current research with regards to platelet rich plasma (PRP), autologous conditioned serum (ACS), autologous protein solutions (APS), and alpha 2 macroglobulin will be analyzed.

RACE# 27059-924918

1 RACE-Approved Credit Hour

07:00 PM

Canine otitis externa is one of the most frequently encountered conditions in small animal veterinary practice. This presentation explores the causes of canine otitis externa including the predisposing, primary and perpetuating factors, the importance of otic cytology, and the essential treatment modalities to help ensure clinical resolution. The development of a long-term maintenance cleaning and allergy management plan will also be discussed.

07:00 PM EST

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

12:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761

Canine Hyperadrenocorticism (Cushing’s Disease) can be a challenging yet rewarding disease to manage. This presentation will review all aspects of Cushing’s: basic pathophysiology, clinical signs, diagnostics, differentiating tests, treatment and monitoring. A series of cases to increase  understanding of managing Cushing’s patients will be presented and the final  section highlights ways to  enhance owner compliance. 

02:00 PM EST

1.5 RACE-Approved Credits  

RACE# 27059-869593 

With dermatologic conditions making up a large volume of the caseload in companion animal medicine and with antimicrobial resistance on the rise, topical therapies need to play a bigger role in dermatologic therapy. This presentation will discuss why topical therapies are helpful and how cytology helps guide topical product choice. The most common active ingredients in topical products for companion animals will be highlighted including their mechanism of action and suggested use. By having a complete understanding of active ingredients, veterinarians will be better equipped to make a topical product selection. Compliance strategies will be discussed to help ensure that what a veterinarian prescribes actually gets used.

02:00 PM EST

RACE# 27059-906349

1 RACE-Approved Credit Hour

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-900255 

This presentation will review the components of an appropriate fluid plan including why fluids are useful, which fluid, and how to calculate the correct volume and rate. In addition, monitoring guidelines to ensure the fluid plan is adequate and appropriate will be discussed. Participants will also learn about the endothelial glycocalyx and its important role in maintaining normal vascular function.

RACE# 27059-743915

1 RACE-Approved Credit Hour

10 PM EST

Canine otitis externa is one of the most frequently encountered conditions in small animal veterinary practice. This presentation explores the causes of canine otitis externa including the predisposing, primary and perpetuating factors, the importance of otic cytology, and the essential treatment modalities to help ensure clinical resolution. The development of a long-term maintenance cleaning and allergy management plan will also be discussed.

02:00 PM EST

RACE# 27059-963682

1 RACE-Approved Credit Hour 
 

With dermatologic conditions making up a large volume of the caseload in companion animal medicine and with antimicrobial resistance on the rise, topical therapies need to play a bigger role in dermatologic therapy. This presentation will discuss why topical therapies are helpful and how cytology helps guide topical product choice. The most common active ingredients in topical products for companion animals will be highlighted including their mechanism of action and suggested use. By having a complete understanding of active ingredients, veterinarians will be better equipped to make a topical product selection. Compliance strategies will be discussed to help ensure that what a veterinarian prescribes actually gets used.

07:00 PM EST

RACE# 27059-906349

1 RACE-Approved Credit Hour

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EST

1 RACE-Approved Credit  

RACE# 27059-918761